AAAbolghasem Allahyari

Abolghasem Allahyari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abolghasem Allahyari has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Alireza Zangooie

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

    4 shared publications
  • Amirhosein Maharati

    Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    4 shared publications
  • Zahra Salehi

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Benyamin Hoseini

    Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

    2 shared publications
  • Maryam Emadzade

    Department of Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

    2 shared publications
  • Maryam Sardarkhani Eydgahi

    Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    2 shared publications

Latest Publications

  • Open Access

    Genetic and clinical insights into the coexistence of multiple myeloma and diffuse large B cell lymphoma from a case report and systematic review with bioinformatics analysis

    by Alireza Zangooie, Moein Piroozkhah, Zahra Ghasemi, Mobin Pirouzkhah, Maryam Sardarkhani Eydgahi, Reza Asgari, Malihe Saberafsharian, Zahra Sanei-Far, Amirhosein Maharati, Zahra Salehi, et al.

    Background Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) are B-cell malignancies that rarely coexist in a single patient, presenting significant diagnostic and therapeutic challenges. While MM primarily involves clonal plasma cells, DLBCL is an aggressive lymphoid neoplasm. Investigating shared genetic mutations and understanding their clinical relevance in both cancers could provide novel insights into their pathogenesis and underlying molecular mechanisms, thereby informing future translational research. Materials and methods A case report was conducted on a 52-year-old male who presented with abdominal pain and anemia. Imaging revealed lymphadenopathy, and biopsy confirmed high-grade DLBCL with concurrent bone marrow involvement suggestive of MM. Laboratory tests identified monoclonal IgM gammopathy, and the patient was treated with R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) chemotherapy for DLBCL followed by autologous stem cell transplantation (ASCT) for MM relapse. A systematic review of the literature was performed using PubMed, Scopus, and Web of Science databases to identify cases of patients diagnosed with both MM and DLBCL. Data on patient demographics, clinical features, treatment regimens, and outcomes were extracted. Additionally, bioinformatics analysis was conducted using publicly available genomic data from cBioPortal and IntOGen to identify driver gene mutations in MM and DLBCL. Functional and pathway enrichment analysis was performed with KEGG and Gene Ontology (GO) databases. Results The case report highlighted a complex clinical course where the patient initially responded well to R-CHOP chemotherapy for DLBCL, achieving remission, but later relapsed with MM, treated with ASCT and lenalidomide. The systematic review revealed 14 eligible studies in which MM and DLBCL often occur in older patients, either simultaneously or sequentially, with variable treatment responses, including complete remission, partial remission, or relapse. The bioinformatics analysis identified several shared function and cancer-related pathways between two cancers including interleukin and cytokine-mediated signaling pathways, regulation of cell cycle, neurotrophin signaling pathway, FOXO signaling pathway, Epstein Barr virus infection, and viral carcinogenesis. Conclusion This study provides valuable insights into the dual occurrence of MM and DLBCL, emphasizing the importance of tailored treatment approaches. The driver mutations identified highlight overlapping oncogenic pathways rather than implying a shared clonal origin, and may inform future studies exploring their biological and clinical implications. Further research into these shared molecular mechanisms could lead to more effective treatments for patients with coexisting MM and DLBCL.

  • Open Access

    Concurrent sigmoid colon adenocarcinoma presenting with cutaneous adult T-cell leukemia/lymphoma: a rare case report

    by Amirhosein Maharati, Alireza Zangooie, Maryam Sardarkhani Eydgahi, Hoda Haghshenas, Zahra Eghbali, Naser Tayyebi Meibodi, Zahra Salehi, Abolghasem Allahyari

    Background: Adult T-cell leukemia/lymphoma (ATLL) is a rare peripheral T-cell malignancy induced by Human T-cell lymphotropic virus type 1 (HTLV-1) infection, commonly affecting individuals in their 50s to 60s. The disease manifests through various clinical forms, with skin involvement being a frequent presentation. While HTLV-1 has been linked to several cancers, including non-ATLL lymphomas and liver cancer. This case report discusses the rare coexistence of sigmoid colon adenocarcinoma and cutaneous ATLL in a 75-year-old woman. Materials and methods: A 75-year-old woman presenting with abdominal pain, vomiting, distention, and constipation underwent clinical evaluation including physical examination, laboratory tests, abdominal imaging, and contrast-enhanced CT. Due to large-bowel obstruction, she received emergency surgical management consisting of left hemicolectomy, splenic flexure mobilization, regional lymphadenectomy, and Hartmann colostomy. Tissue from the resected colon and later cutaneous lesions was submitted for histopathological examination and immunophenotypic profiling with an extended T-cell marker panel. Serologic testing for HTLV-1 was also performed. Additionally, a systematic literature review was conducted according to PRISMA 2020 guidelines. Comprehensive searches of PubMed, Scopus, and Web of Science from database inception to November 3, 2025, used controlled vocabulary and free-text terms related to HTLV-1/ATLL and gastrointestinal malignancies. Case reports and case series involving human subjects were independently screened in two phases. Results: The patient was diagnosed with sigmoid colon adenocarcinoma requiring emergency surgery and later developed cutaneous lesions, which were confirmed as smoldering ATLL through histopathology, immunophenotyping (mature CD4 + /CD25 + T-cell phenotype with CD7 loss), and positive HTLV-1 serology. She is receiving adjuvant chemotherapy for colorectal cancer while undergoing surveillance for ATLL. The systematic search identified 365 records; after removal of duplicates and screening, four eligible publications were included. Of these four studies, three were case reports, all describing patients with HTLV-1 infection and gastric adenocarcinoma. The fourth publication was a case series including three patients; two of them ATLL and gastric adenocarcinoma, consistent with the findings of our study, while the third patient had ATLL and colorectal adenocarcinoma. Overall, the reported clinical outcomes varied, underscoring the rarity of this coexistence and the lack of standardized management approaches. Conclusion: This case highlights the rare occurrence of sigmoid colon adenocarcinoma and cutaneous ATLL in an HTLV-1-positive patient, emphasizing the potential for HTLV-1 to contribute to multiple malignancies. Our findings underscore the need for further research to explore the link between HTLV1 and gastrointestinal cancers, as well as its broader oncogenic potential in other malignancies. The coexistence of these two diseases presents diagnostic challenges and calls for an integrated approach to patient management in HTLV-1-endemic areas.

  • Open Access

    Aseptic Meningitis as First Presentation of Acute Myeloid Leukemia With Normal Cell Blood Count

    by Mahnaz Arian, Abolghasem Allahyari, Marzieh Kazerani, Ahmadreza Zarifian, Kiana Ketabi, Hossein Alavi, Melika Farshidianfar

    Aseptic meningitis can be the initial manifestation of acute myeloid leukemia (AML), even when the complete blood count (CBC) is normal. A single cerebrospinal fluid (CSF) analysis for malignant cells may be insufficient and could delay diagnosis. Therefore, infections, collagen vascular diseases, and malignancies—particularly leukemias—should be carefully considered.

  • Open Access

    Essential thrombocythemia as an initial presentation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with complete response to the bortezomib, cyclophosphamide, dexamethasone regimen: a case report

    by Alireza Zangooie, Zahra Moradi, Reza Asgari, Amirhosein Maharati, Zahra Salehi, Abolghasem Allahyari

    Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome is a rare paraneoplastic disorder often presenting with atypical manifestations, making diagnosis challenging. This case is novel due to the rare presentation of essential thrombocythemia as the initial manifestation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome. Furthermore, it highlights the remarkable therapeutic response, achieving a complete remission following treatment with the bortezomib, cyclophosphamide, dexamethasone regimen, underscoring this combination therapy’s efficacy in managing such complex cases. A 65-year-old Iranian woman presented with fatigue, headache, and thrombocytosis, leading to a diagnosis of essential thrombocythemia. Over time, her condition progressed with the development of neuropathy and persistence of thrombocytosis, which warranted further investigation. Imaging revealed multiple lymphadenopathies, sclerotic bone lesions, and ascitic fluid, raising suspicion for a plasma cell dyscrasia. Bone marrow biopsy, lymph node biopsy, and elevated vascular endothelial growth factor levels confirmed the diagnosis of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome. The patient was treated with bortezomib, cyclophosphamide, dexamethasone chemotherapy regimen, resulting in complete symptom relief, normalization of the complete blood count, and significant improvement in imaging findings. This case highlights the need to recognize atypical polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome presentations, such as essential thrombocythemia, for timely diagnosis and underscores the bortezomib, cyclophosphamide, dexamethasone regimen’s efficacy in achieving complete remission.

  • Open Access

    Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial

    by Hedyieh Karbasforooshan, Hossein Rahimi, Omid Arasteh, Abolghasem Allahyari, Mehdi Varmaghani, Mahdi Jannati, Vahid Ghavami, Mahmoodreza Jaafari, Sepideh Elyasi

    Background: Folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and oxaliplatin and capecitabine (XELOX) are the most widely used chemotherapy regimens for treating metastatic colorectal carcinoma (CRC). These regimens are associated with various adverse reactions, including neuropathy and hand-foot syndrome (HFS). Silymarin, a flavonoid derived from Silybum marianum, has a wide range of biological activities. It has been used to counteract chemotherapy side effects due to its antioxidant, anti-apoptotic, and anti-inflammatory properties. Objectives: The purpose of this study was to assess the preventive effect of nano-silymarin on neuropathy and HFS induced by the FOLFOX6 and XELOX regimens. Methods: A randomized, triple-blinded, placebo-controlled clinical trial was conducted on 60 patients who were randomly assigned to receive 70 mg capsules containing 15% silymarin nano micelles twice a day after meals, starting from the first day of the first chemotherapy course and continuing for six courses of the XELOX or m-FOLFOX6 regimen. The severity of adverse effects was assessed after the third and sixth courses based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5. Results: The median CTCAE scores for HFS and neuropathy were significantly lower in the nano-silymarin group at the end of the third course (P < 0.001). However, the difference remained significant only for HFS at the end of the sixth course (P = 0.022). Additionally, the scores increased significantly in both the placebo and nano-silymarin groups during the therapy (P < 0.05). Conclusions: Nano-silymarin may be considered an adjuvant medication for the prevention of certain chemotherapy-induced adverse reactions. Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation.


  • Open Access

    Pathologic Response Rates in Patients with Gastric Cancer Following FLOT Neoadjuvant Chemotherapy

    by Samaneh Sajjadi, Mostafa Kamandi, Abolghasem Allahyari, Sajjad Ataei Azimi, Alireza Baari, Niloufar Valizadeh, Farbod Hatami

    Background: Gastric adenocarcinoma is among the most prevalent cancers associated with a high mortality rate. The multidrug neoadjuvant chemotherapy administered before and after surgery has attracted attention as a beneficial standard of care for managing this malignancy. Objectives: This study assessed the pathologic response of patients with gastric cancer who were treated with fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT). Methods: Patients with pathologically confirmed gastric adenocarcinoma without distant metastases were enrolled in this retrospective cohort study conducted at Imam Reza and Ghaem hospitals in Mashhad. Data regarding demographics, tumor status, treatment toxicity, and pathology results were collected using a predesigned questionnaire after four cycles of FLOT neoadjuvant chemotherapy. SPSS-26.0 was utilized to analyze the data, and a significance level of P < 0.05 was applied. Results: We evaluated data from 53 cases with a mean age of 51.1 ± 9.7 years. Diffuse adenocarcinoma was the most common finding in histology (54.7%). Pathologic complete response was observed in 16 (30.2%) patients. Most (69.8%) patients received only 7 out of 8 planned cycles. Concerning surgical margin, 46 (86.8%) patients achieved R0 tumor resection. Pathologic complete response was not significantly linked with age (P = 0.91), sex (P = 0.65), performance status (P = 0.2), tumor histology (P = 0.14), tumor grading (P = 0.07), tumor location (P = 0.8), and the number of neoadjuvant chemotherapy cycles (P = 0.9). Conclusions: Our findings demonstrated the relative clinical efficacy of neoadjuvant chemotherapy with the FLOT regimen administered before and after surgery. However, due to chemotherapy-related side effects, patients may not adhere to all eight prescribed cycles of chemotherapy.


  • Plasma microRNA-195, −34c, and − 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients

    by Zohreh Rezaei, Kazem Dastjerdi, Abolghasem Allahyari, Soodabeh ShahidSales, Sahar Talebian, Amirhosein Maharati, Alireza Zangooie, Amir Sadra Zangouei, Farzad Sadri, Saman Sargazi


  • Open Access

    Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia

    by Maryam Khodashenas, Arezoo Rajabian, Armin Attaranzadeh, Fahimeh Lavi Arab, Negin Allahyari, Abolghasem Allahyari

    This study aimed to assess the patterns of serum cytokines in chronic lymphocytic leukemia patients at baseline and post-chemotherapy and investigate their association with response to treatment and chronic lymphocytic leukemia prognosis. Blood samples were taken from 32 subjects at their first medical visit after being diagnosed with chronic lymphocytic leukemia and 1 year after chemotherapy. Then, levels of cytokines and blood parameters in peripheral blood were measured. Correlation analysis was used to assess the indexes before and after chemotherapy as well as at different disease stages. Most of the patients (45.80%) had stages I and III before initiation of treatment and after treatment, respectively. There were significant differences between levels of interleukin (IL)-6 (p=0.006) and IL-10 (p=0.009) before and after treatment. Notably, the difference in IL-10 levels before and after treatment was significantly higher in the advanced stages compared to that in the non-advanced stages (p=0.007). IL-6 and IL-10 were also higher in the expired patients compared to the survived cases. Cytokines such as IL-6 and IL-10 may be considered predicting factors for chronic lymphocytic leukemia prognosis.


  • Open Access

    Clinical characteristics of 200 COVID-19 patients in Mashhad, Iran, February and March 2020

    by Mina AkbariRad, Abolghasem Allahyari, Sahar Ravanshad, Shima Nabavi Mahali, Farnoosh Ebrahimzadeh, Mahnaz Mozdourian, Zahra Javidarabshahi, Mohsen Seddigh-Shamsi, Maryam Emadzade, AmirAli Moodi Ghalibaf

    Introduction: Coronavirus disease 2019 (COVID-19) is a pulmonary involvement which was reported for the first time in December 2019 in the city of Wuhan, Hubei province, China. The aim of the study was to describe the demographic, clinical, laboratory, and radiological characteristics of 204 definitive laboratory-confirmed COVID-19 patients hospitalized in Mashhad, Khorasan Razavi province, Iran. Patients and Methods: This study was performed on 204 laboratory-confirmed COVID-19 patients. A set of laboratory tests combined with various patient information and results from lung high-resolution computed tomography (HRCT) were gathered in a checklist and analyzed to give us a better view of patients who are hospitalized due to the complications caused by this disease. Results: The average age of our patients was 58.83 ± 15.93 years. There were 122 (59.8%) male and 82 (40.2%) female patients, and almost all of our patients had at least one underlying disease. Nine (4.4%) of our patients reported having gone for a trip to COVID-19-epidemic areas in the last 2 weeks. The most common signs shared among all our patients were cough, fever, and decreased O2 saturation; the average respiratory rate was 25.50 ± 6.74/min, average axillary body temperature was 37.69°C ± 0.69°C, and average O2 saturation was 88.34% ± 7.34%. Conclusion: Based on our results, the most common signs of this disease are fever, cough, and shortness of breath, similar to seasonal influenza. Our data on disease severity showed that 33 (16.2%) patients had moderate disease, 139 (68.1%) had severe disease, and 28 (13.7%) were critical; 22 (10.8%) of our hospitalized patients died due to the complications of this disease.


  • Open Access

    Intravenous Immunoglobulin for Treatment of Patients with COVID-19: A Case-control Study

    by Rozita Khodashahi, Hamid Reza Naderi, Alireza Sedaghat, Abolghasem Allahyari, Soroush Sarjamee, Soudabe Eshaghi, Farzaneh Fazeli, Benyamin Hoseini, Maliheh Dadgarmoghaddam, Mandana Khodashahi

    Background: It seems that the risk of developing complications associated with coronavirus disease 2019 (COVID-19) is higher among individuals with weakened immune systems. Objectives: Therefore, this study was carried out to determine the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of patients not entering the intubation phase compared to those entering the intubation phase. Methods: This descriptive case-control study was performed on 26 patients with COVID-19 referring to Imam Reza hospital in Mashhad, Iran, in March 2020. For subjects with COVID-19 not responding to the standard three-drug protocol (i.e., ribavirin, hydroxychloroquine, and lopinavir/ritonavir), three doses of IVIG (0.4 g/kg/day) were added to the protocol. The patients were divided into two groups of subjects not entering the intubation phase and those entering the intubation phase and compared in terms of different variables. Results: The comparison of laboratory findings showed a significant difference before and after receiving IVIG regarding oxygen saturation (P < 0.005), white blood cell (P = 0.001), hemoglobin level (P = 0.0002), lymphocyte count (P = 0.03), and C-reactive protein (P = 0.001). In general, 53.8% and 46.2% of the patients were discharged and expired, respectively. All the subjects not entering the intubation phase were recovered; nevertheless, only one case entering the intubation phase was recovered, and 92.3% of the patients expired. A significant difference was observed between the patients not entering the intubation phase and those entering the intubation phase in terms of mortality (χ2 = 22.28; P < 0.005). Conclusions: In summary, the obtained results of the current study confirmed the therapeutic effects of IVIG on patients with COVID-19. Moreover, better treatment results, shorter hospital stay, and lower mortality rates were observed among COVID-19 patients who did not enter the intubation phase in comparison with those entering the intubation phase.